PLSE Stock: Price, Earnings History and SEC Filings
Pulse Biosciences, Inc. (PLSE) last traded at $52.24, down 5.84% on the latest session and up 4.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.36 against an analyst estimate of $-0.31, a miss of 16.1%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
PLSE earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.36 | $-0.31 | -16.13% |
| Mar 2026 | May 4, 2026 | $-0.27 | $-0.32 | +15.62% |
| Dec 2025 | Feb 19, 2026 | $-0.26 | $-0.32 | +18.75% |
| Sep 2025 | Nov 5, 2025 | $-0.29 | $-0.31 | +6.45% |
PLSE beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How PLSE reacts to earnings
Across its last 8 earnings releases, PLSE moved 6.6% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | After close | +10.90% |
| 2026-05-04 | Before open | -3.84% |
| 2026-02-19 | After close | -14.59% |
| 2025-11-05 | After close | -3.32% |
| 2025-08-12 | After close | +11.19% |
| 2025-05-08 | After close | +1.31% |
| 2025-03-28 | Before open | +6.00% |
| 2024-10-30 | After close | -1.64% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
PLSE financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $350000 | -$73M | -$54M | -20794.6% | – |
| 2024 | $0 | -$54M | -$36M | – | – |
| 2023 | $0 | -$42M | -$33M | – | – |
| 2022 | $700000 | -$59M | -$47M | -8357.9% | – |
| 2021 | $1M | -$64M | -$55M | -4489.4% | – |
| 2020 | $0 | -$50M | -$36M | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for PLSE
- 8-K · Oct 14, 2026Other events, Financial statements and exhibits
- 8-K · Oct 7, 2026Other events, Financial statements and exhibits
- 8-K · Sep 15, 2026Material agreement, Agreement terminated, Financial statements and exhibits
- 424B5 · Sep 15, 2026
- 8-K · Sep 15, 2026Other events, Financial statements and exhibits
- 8-K · Aug 6, 2026Material agreement, Financial statements and exhibits
- 424B5 · Aug 6, 2026
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 29, 2026Other events, Financial statements and exhibits
Insider filing activity
PLSE insiders filed 4 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
PLSE news
- DexCom (DXCM) Surpasses Q3 Earnings and Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Pulse Biosciences to Present at Stifel 2026 Healthcare ConferenceOct 29, 2026 · finance.yahoo.com
- Pulse Biosciences (PLSE) Stock Still Seems Rich Against Book ValueOct 25, 2026 · finance.yahoo.com
- Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026Oct 22, 2026 · finance.yahoo.com
About Pulse Biosciences, Inc.
Pulse Biosciences, Inc. (PLSE) is a US-listed public company on Nasdaq. The SEC classifies its business as Surgical & Medical Instruments & Apparatus. It is incorporated in DE. Its fiscal year ends in December.